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Background: TNFa is a cytokine that may contribute to the pathophysiology of airway
inflammation. Inhalation of TNFa produces granulocyte recruitment and airway hyperre-
sponsiveness in man. Anti-TNFa treatment may inhibit allergen-induced plasma exudation
in guinea-pig airways. Increased nasal mucosal output of TNFa has been demonstrated in
allergic rhinitis, but the effect of TNFa on the human nasal mucosa has not been examined
in vivo.
Objective: To examine effects of topical TNFa on the human nasal mucosa in vivo.
Methods: In a dose-finding study, healthy subjects received intranasal TNFa (0–7.5mg).
Nasal lavages were carried out before as well as 10min and 24 h post challenge and a2-
macroglobulin was measured as an index of plasma exudation. In a second study, involving
patients with allergic rhinitis examined out of season, a sham-controlled nasal challenge
with TNFa (10 mg) was performed and followed 24 h later by an allergen challenge. Lavages
were performed before the TNFa challenge, 24 h thereafter, and 10min post allergen
challenge. a2-Macroglobulin, eosinophil cationic protein (ECP), myeloperoxidase (MPO),
and IL-8 were analyzed as indices of plasma exudation, eosinophil activity, neutrophil
activity, and pro-inflammatory cytokine production, respectively.
Results: In the dose-finding study, TNFa produced significant increases in a2-macroglobulin
24 h post challenge (po0.01). In allergic rhinitis, 10 mg of TNFa also produced this effect
(po0.01) as well as increases in ECP and IL-8 (po0.01). MPO was increased 24 h post
challenge, but this change did not reach statistical significance. TNFa did not produce any
acute effects and did not affect the responsiveness to allergen.
Conclusion: The present study demonstrates that topical TNFa produces a human nasal
inflammatory response. These data suggest a role of TNFa in nasal conditions characterized
by mucosal inflammation.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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TNFa is a pro-inflammatory mediator involved in the
pathophysiology of a range of inflammatory conditions.
Frequently explored areas are autoimmune conditions such
as rheumatoid arthritis and Crohn’s disease, which are today
successfully treated with TNFa-inhibitors.1
The role of TNFa in conditions characterized by airway
inflammation is currently under investigation focusing on
the bronchial airways. Yu et al.2 have shown increased
bronchoalveolar lavage (BAL) cell expression of TNFa mRNA
following airway allergen challenge in allergic mice. Inhala-
tion of TNFa in rats has been demonstrated to produce BAL
neutrophilia and airway hyperresponsiveness.3 In experi-
mental models of asthma, blockade of TNFa activity has
been shown to reduce allergen-induced airway extravasa-
tion of plasma and granulocyte recruitment.2,4–6 In human
bronchial airways, TNFa is produced by a number of cell
types, including macrophages,7 eosinophils,8,9 epithelial
cells,10,11 and mast cells.12,13 Inhalation of TNFa produces
an inflammatory response characterized by increased
sputum numbers of neutrophils and eosinophils as well as
by development of airway hyperresponsiveness.14,15
Furthermore, recent studies have shown that treatment
with etanercept, a soluble TNFa receptor-IgG1 Fc fusion
protein, is associated with improvement in asthma symp-
toms, lung function, and airway hyperresponsiveness in
refractory asthma.16,17
Potentially reflecting the pathophysiological similarities
between airway inflammation in allergic rhinitis and
asthma, patients suffering from allergic rhinitis have been
shown to feature increased tissue expression of TNFa mRNA
as well as increased nasal mucosal output of the TNFa
protein.18–20 However, information on the role of TNFa in
human nasal airways is limited. Notably, to the best of our
knowledge, there is no information on the consequences to
the nasal airway and to allergic rhinitis of increased TNFa
activity. One way of exploring this, again in analogy with the
bronchial airways,14,15 would be to examine effects of TNFa
topically applied on the nasal mucosa.
In the present study, we have thus examined effects
of topical TNFa on the human nasal mucosa. First, increas-
ing doses were given to healthy subjects, and nasal
symptoms and PIF (peak inspiratory flow) were monitored.
Also, nasal lavages were carried out and levels of a2-
macroglobulin were monitored as an index of plasma
exudation. Secondly, an exudation-producing dose of
TNFa was given to patients with seasonal allergic rhinitis
(out of season). Nasal lavages were carried out 24 h post
challenge and lavage fluid levels of a2-macroglobulin,
eosinophil cationic protein (ECP), myeloperoxidase (MPO),
and interleukin-8 (IL-8) were measured as indices of
inflammation. In addition, a nasal allergen challenge was
carried out immediately after the 24 h lavage, and this
measure was also followed by a lavage and again by ana-
lysis of a2-macroglobulin, ECP, MPO, and IL-8. The ra-
tionale for employing an allergen challenge was that
patients with allergic rhinitis often feature a variable
responsiveness to allergen depending of the underly-
ing inflammatory activity. Accordingly, we hypothesized
that an inflammatory effect of TNFa could change the
responsiveness to allergen.Material and methods
Study design
Subjects were challenged intranasally with TNFa. Healthy
individuals were recruited to a dose-finding study and,
subsequently, patients with allergic rhinitis were recruited
to a principal study. Written informed consent was obtained
and the study was approved by the regional ethics
committee.
Dose-finding study
Ten healthy volunteers (9 males, 1 female) aged between 18
and 27 participated in the study. Prior to the first challenge
all subjects were subjected to an interview, a general health
examination, a nasal examination, and a skin prick test.
Inclusion criteria were: A negative skin prick test, a normal
nasal examination, and use of contraceptives (for females).
Exclusion criteria were: A history of upper respiratory tract
infection within a period of 7 days before the start of the
study, allergic and non-allergic rhinitis, other nasal disease
(structural abnormalities, rhinosinusitis, nasal polyposis),
use of nasal decongestants within a period of seven days
before the start of the study, other pharmacological
treatments (except occasional analgesics) within a period
of 1 month prior to the study.
Intranasal challenges with isotonic saline and escalating
doses of TNFa were carried out. The doses of TNFa were 0.3,
1.5, and 7.5mg, and between the challenges washout periods
of seven days were instituted. Nasal lavages were carried out
5min before, 10min after, and 24h after every challenge.
Also, two 30 s lavages were carried out immediately prior to
the TNFa challenge (these lavages were employed to produce
a low baseline and were not collected). Nasal lavage levels of
a2-macroglobulin were measured as an index of plasma
exudation. Prior to each nasal lavage the subjects scored
nasal symptoms and monitored nasal PIF (peak inspiratory
flow) using a specific flow meter (Clement-Clarke, Harlow,
UK). Sneezes, secretion, and blockage were each scored on a
scale from 0 to 3. The scores were added to a total nasal
symptom score (range 0–9).
Principal study
Sixteen patients with allergic rhinitis (11 males, 5 females)
aged between 24 and 35 participated in the study. All
subjects were subjected to an interview, a general health
examination, a nasal examination, and a skin prick test.
Inclusion and exclusion criteria were the same as described
above except that these subjects presented a history of at
least 2 years of seasonal allergic rhinitis and a positive skin
prick test to relevant aeroallergens.
Nasal spray-challenges with 10mg of TNFa and isotonic
saline were carried out in a crossover, randomized, and sham-
controlled design. A washout period of 2 weeks was instituted
between the challenges. Twenty-four hours after each
challenge, the patients were subjected to a nasal allergen
challenge (1000 SQ-U of either birch or grass pollen allergen).
Nasal saline lavages were carried out 5min before each TNFa
challenge, 24h thereafter (just before the allergen chal-
lenge), and 10min after each allergen challenge. Also, two
30 s lavages were carried out immediately prior to the TNFa
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Figure 1 Effects of intranasal TNFa and sham challenge on
nasal lavage fluid levels of a2-macroglobulin in healthy subjects.
The challenges were separated by at least 7 days. Nasal lavages
were carried out before each challenge (pre-challenge) as well
as 10min and 24 h thereafter. TNFa produced significant
increases in lavage fluid levels of a2-macroglobulin 24 h post
challenge, whereas no such effect was observed at 10min post
challenge (**po0.01).
H. Widegren et al.1984challenge (these lavages were not collected). Nasal lavage
levels of a2-macroglobulin, IL-8, ECP, and MPO, and were
measured as indices of plasma exudation, pro-inflammatory
cytokine production, eosinophil activity, and neutrophil
activity, respectively. Prior to the challenge, 24h after
sham/TNFa challenge, and 10min following the allergen
challenge sneezes, secretion, and blockage were scored as
described above.
TNFa challenge and nasal lavages
Recombinant human TNFa (210-TA/CF, R&D Systems, Abing-
don, UK) was mixed with isotonic saline to concentrations
where 100 ml of each solution contained the preferred
amounts of TNFa. The TNFa-solution was prepared less then
1 h before the challenge and it was administered using a
spray-device delivering 100 ml per actuation. At all times the
challenges and lavages were administered to the right hand
side nasal cavity. The lavages were carried out using a pool-
device containing 15ml of isotonic saline.21 The lavage fluids
were kept in the right nasal cavity for 5min. The recovered
lavage fluid was centrifuged and the supernatant was
homogenized, prepared in aliquots, and frozen (30 1C)
for later analysis.
Analyses
a2-Macroglobulin was measured using a radioimmunoassay
sensitive to 7.8 ng/ml. Rabbit anti-human a2-macroglobulin
(Dakopatts, Copenhagen, Denmark) was used as anti-serum
and human serum (Behringwerke, Marburg, Germany) as
standard. Human a2-macroglobulin (Capell-Organon, Turnh-
out, Belgium) was iodinated using a lactoperoxidase
method. Tracer and standard/sample was mixed with
antiserum before adding goat anti-rabbit anti-serum (As-
traZeneca, Lund, Sweden). The bound fraction was mea-
sured using a gamma counter. The intra- and inter-assay
coefficients of variation were between 3.8–6.0% and
3.1–7.2%, respectively. IL-8 was measured using a commer-
cially available enzyme-linked immunosorbent assay (R&D
Systems, Abingdon, UK). ECP and MPO were also measured
using commercially available assays (Pharmacia, Uppsala,
Sweden). The limits of detection for IL-8, ECP, and MPO were
31.2 pg/ml, 2.0, and 1.6 ng/ml, respectively.
Statistics
In healthy subjects, differences in levels of a2-macroglobulin
between observation at different TNFa doses were analyzed
by the Friedman test and, if statistical significance was
achieved, by the Wilcoxon signed rank test. In patients with
allergic rhinitis, differences in symptoms and lavage fluid
levels of a2-macroglobulin, IL-8, ECP, and MPO were analyzed
using the Wilcoxon signed rank test. A p-value of o0.05 was
considered significant. Data are presented as mean7SEM.
Results
In the dose-finding study, intranasal challenge with TNFa
produced a significant increase in lavage fluid levels of a2-macroglobulin as recorded 24 h post challenge (po0.01). In
contrast, no such effect was observed 10min post challenge
(Fig. 1). No significant changes in nasal symptoms or nasal
PIF were observed at any time point or at any challenge dose
(data not shown).
In patients with allergic rhinitis, challenge with 10 mg
of TNFa produced significant increases in lavage levels of
a2-macroglobulin 24 h post challenge (cf. sham challenge)
(Fig. 2a). In addition, significant increases were observed for
IL-8 and ECP at this time point (Fig. 2b and c). Nasal lavage
fluid levels of MPO were also increased 24 h post challenge,
but this change failed to reach statistical significance
(p ¼ 0.09) (Fig. 2d). TNFa produced low-grade nasal
symptoms 24 h post challenge (cf. sham challenge) (Table 1).
In sham challenged subjects, levels of a2-macroglobulin
were significantly increased 10min post allergen challenge,
compared with pre allergen challenge (24 h) levels
(po0.01). Also, the allergen challenge produced significant
nasal symptoms (Table 1): score 5 out of 9 (po0.001).
The symptom score recorded post allergen challenge was
not affected by TNFa administration 24 h earlier (Table 1).
Similarly, with the exception of MPO, the lavage fluid
indices recorded post allergen challenge were unaffected by
prior TNFa administration (cf. sham challenge) (Fig. 2a–d).
Post allergen challenge MPO levels increased significantly
following TNFa administration (po0.05) (cf. sham chal-
lenge) (Fig. 2d).
In the principal study, at the 24 h observation (i.e., the
point in time when the effect of TNFa was compared to the
sham challenge) the overall percentage of nasal lavages
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Figure 2 Effects of nasal TNFa and sham challenge on lavage fluid levels of a2-macroglobulin (a), IL-8 (b), ECP (c), and MPO (d) in
patients with allergic rhinitis examined outside the pollen season. The lavages were carried out before each challenge (pre-
challenge) and 24 thereafter (24 h). In addition, lavages were carried out 10min after an allergen challenge that in turn was carried
out 24 h after the sham/TNFa challenge (24 h+allergen). TNFa significantly increased the lavage fluid levels of IL-8, ECP, and a2-
macroglobulin. An increase in MPO was also observed following TNFa, but this change only reached borderline significance (p ¼ 0.09).
The responsiveness to allergen was significantly increased following TNFa challenge for MPO (d), but not for the other employed
lavage fluid indices (*po0.05, **po0.01).
Effects of TNFa on the nasal mucosa 1985with levels of IL-8, ECP, and MPO below the limit of
detection was 0%, 19%, and 0%, respectively.Discussion
The present study, involving healthy subjects as well as
patients with allergic rhinitis, has shown that TNFa produces
plasma exudation when applied topically onto the nasal
mucosa. This response is associated with pro-inflammatorycytokine production (IL-8) and increased granulocyte activ-
ity. The observations are of interest in the context of
viewing TNFa as a mediator of potential importance to nasal
airway defence as well as to the pathophysiology of nasal
conditions characterized by inflammation.
The selection of the first dose of the present challenge-
series was based on a study by Thomas et al.14 in which
humans inhaled 60 ng of TNFa to the lower airways. At this
dose-level, none of eight subjects were reported to
experience symptoms suggestive of systemic effects,
ARTICLE IN PRESS
Table 1 Nasal symptom scores (mean7SEM, range 0–9)
recorded prior to any challenge, 24 h after sham/TNFa
challenge, and following allergen challenge (performed
24 h after the sham/TNFa challenge).
Sham TNFa
Pre-challenge 0.470.2 0.670.2
24 h post-challenge 0.470.2 1.170.3**
Post-allergen challenge 5.070.6 5.970.3
TNFa produced low-grade but significant symptoms (cf. sham
challenge).**po0.01.
Allergen produced marked symptoms, which were unaffected
by prior TNFa administration.
H. Widegren et al.1986whereas the authors observed a leftward shift in the
dose–response curve to methacholine and a significant rise
in the levels of polymorphonuclear cells in sputum. For
safety reasons we examined healthy subjects first: As we
increased the dose of TNFa from 0.3 to 7.5 mg all subjects
remained symptomless and no adverse events occurred. For
our principal study, involving patients with allergic rhinitis,
10 mg of TNFa was chosen as challenge dose to assure a
positive response. This dose produced only low-grade nasal
symptoms (score about 1 on a scale from 0 to 9) and no
adverse effect. Accordingly, we conclude that TNFa in the
present dose-range is safe as an experimental, nasal
challenge agent.
Based on preliminary observations on acute plasma
exudation producing effects of TNFa in guinea-pig airways
(Greiff et al., unpublished), suggesting that TNFa may act as
a direct microvascular permeability increasing mediator, we
selected nasal lavage fluid levels of the plasma protein a2-
macroglobulin as index in our dose-finding study.22 We could
demonstrate that TNFa induced plasma exudation in the
human nasal airway. However, whereas TNFa produced this
effect 24 h post challenge, no plasma exudation was
observed acutely (10min post challenge). Our observation
suggests species differences between humans and rodents.
Such differences have previously been shown and may be
attributable to a differential ability of sensory nerves to
evoke and mediate exudative, neurogenic inflammation.22
We cannot exclude that even higher doses of TNFa would
have produced acute plasma exudation in our challenge
model. However, the present observation suggests that
TNFa-induced plasma exudation 24 h post challenge does not
reflect a direct microvascular action of the mediator, but
rather a secondary response to increased cellular inflamma-
tion (below). Our finding suggests the possibility that TNFa
can be a pro-inflammatory mediator in the human nasal
airway.
In the present study, the nasal output of ECP and MPO was
increased 24 h post TNFa challenge. Whereas this effect was
statistically significant for ECP, it reached borderline
significance for MPO (p ¼ 0.09). In addition to ECP and
MPO, the output of the pro-inflammatory chemokine IL-8
was also increased. These findings are in keeping with
observations in man on increased numbers of granulocytes in
sputum following TNFa inhalation.14 It is also in agreement
with reports showing that treatment with a soluble TNFa
receptor, reducing the levels of free TNFa, attenuatesperibronchial eosinophil and neutrophil infiltration in aller-
gic mice.4 Furthermore, our data support in vitro findings by
Yamagishi et al.23 on reduced epithelial cell production of
IL-8 following TNFa-antibody treatment. Taken together,
available data suggest that TNFa is involved in mounting
airway granulocyte responses, in part through increased IL-8
activity,24 and that this mechanism is valid also for the
human nasal airway. Additional studies are warranted to
further explore this effect of TNFa and tentatively such
approaches should comprise lavage as well as tissue
observations.
The present allergen challenge performed 24 h post sham
challenge produced symptoms of allergic rhinitis as well as
significant plasma exudation. These responses, and the
employed lavage fluid indices with the exception of MPO,
were not significantly affected by TNFa administration (cf.
sham challenge). Our observations suggest the possibility
that TNFa may not be critically involved in the pathophy-
siology of allergen responsiveness in allergic rhinitis. Some-
what in contrast, Thomas et al.14,15 demonstrated increased
airway responsiveness to methacholine 24 h after inhalation
of TNFa in normal subjects as well as in mild asthmatics.
Furthermore, Renzetti et al.6 reported that pre-treatment
of allergic guinea-pigs with an anti-TNFa-agent reduced the
airway responsiveness to substance P. Differences between
challenge agents (allergen versus methacholine/substance
P), between nasal and bronchial airways, and between
species may explain the above discrepancies. Also, we
cannot exclude that a greater dose of TNFa would have
produced a different result in the present study. The
strength of our observation lies in the fact that it involves
humans and a clean, acute type-1 allergic reaction, as
opposed to a more complex inflammatory condition that
characterizes asthma. Further studies, tentatively compris-
ing anti-TNFa measures, are warranted to explore whether
or not TNFa has a role in allergic rhinitis.
Our observation that levels of MPO recorded post allergen
challenge was significantly increased by TNFa may suggest a
development of ‘‘hyperresponsiveness’’, in this case a
situation where the nasal mucosa is prone to mount a
neutrophil response. However, the allergen challenge may
not per se have produced the increase in neutrophil activity.
Alternatively, it may be speculated that TNFa per se
produced a limited neutrophil degranulation, as suggested
by the present study, and that the luminal entry of MPO was
facilitated by the allergen-induced plasma exudation re-
sponse. Such a mechanism has previously been demon-
strated for other inflammatory mediators.22 Further studies
involving additional neutrophil markers and detailed ana-
lyses of nasal biopsies are needed to clarify this issue.
A study involving patients with allergic rhinitis examined
out of season has shown that treatment with a clinical dose
of an antihistamine (fexofenadine) may not affect elevated
levels of TNFa in nasal secretions observed following nasal
allergen-challenge.20 Similarly, Benson et al.25 have demon-
strated that a topical corticosteroid (budesonide) does not
reduce the levels of TNFa in nasal fluids obtained from
children with seasonal allergic rhinitis. In the context of
viewing anti-TNFa drugs as treatment candidates for
airway conditions characterized by allergic airway inflam-
mation, it is of interest to note that TNFa production may be
little affected by such key anti-allergy pharmaceuticals.
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Effects of TNFa on the nasal mucosa 1987Accordingly, drugs that reduce TNFa activities may add to
current airway therapeutic approaches. A role for anti-TNFa
in the treatment of inflammatory airway conditions is
suggested by the present observations and by other airway
observations on pro-inflammatory effects of TNFa as well as
by recent reports of beneficial effects of anti-TNFa treat-
ment in asthma.14–17 A role in allergic inflammation may not
be excluded by the present observation that TNFa (cf. sham
challenge) did not affect the response to an allergen
challenge since the dose–response relationship, as well as
the time-response relationship, has not been fully explored.
Whether or not TNFa inhibiting drugs have a role in the
treatment of nasal conditions characterized by inflamma-
tion, including allergic rhinitis, remains to be clarified.
We conclude that TNFa produces pro-inflammatory
effects in human nasal airways, but that TNFa may not
affect the responsiveness to allergen.
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